Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
CVS$80.90+0.91(+1.14%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETGOOG$289.65+2.35(+0.82%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETINTC$56.95-1.33(-2.28%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,459.49-36.65(-2.45%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$317.20-8.50(-2.61%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.71+0.54(+1.17%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.87+1.01(+0.99%)Transaction in Own Shares8:00:53 AM ETIBM$256.39+2.07(+0.81%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$633.55+3.55(+0.56%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$289.65+2.35(+0.82%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$354.53+5.02(+1.44%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$216.81+17.35(+8.70%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.39+2.07(+0.81%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ETNVDA$197.03-3.26(-1.63%)Nvidia Stock Is Back at $200. What History Suggests Is the Floor.7:57:00 AM ETAAPL$354.53+5.02(+1.44%)Apple: Demand Is Not The Problem7:54:50 AM ETCOP$139.45+2.51(+1.83%)BRIEF-ConocoPhillips Says Qatar LNG Production Remained Constrained Through Q37:50:36 AM ETMCD$280.65+0.43(+0.15%)McDonald's Is Rallying, but Can You Sleep at Night Owning It?7:48:44 AM ETPLTR$167.00-4.70(-2.74%)Palantir's CEO Just Said What Wall Street Doesn't Want to Hear About AI7:47:36 AM ETMSFT$556.87+1.07(+0.19%)The Same $10,000 in Microsoft and Meta Could Produce Very Different Results by 20307:47:14 AM ETQCOM$153.72-19.47(-11.24%)Wall Street Breakfast Podcast: The VIX Plunges In Post-Election Rally7:47:00 AM ETKO$96.92+1.04(+1.08%)If You'd Invested $1,000 Alongside Warren Buffett in Coca-Cola, Here's How Much You'd Have Today7:47:00 AM ET

PCSA · NASDAQ

Processa Pharmaceuticals, Inc.

$1.95 +0.02 (+1.04%)

Company overview

Processa Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog in Phase 2B clinical trials for pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase in Phase 1B clinical trials for me…

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$5.5M
Employees
10
Headquarters
Hanover, MD
Website
processapharmaceuticals.com
CEO
George K. Ng
Listed
March 7, 2014
P/E
-0.18
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$301
Operating income
-$14.5M
EBITDA
-$14.5M
Net income
-$14.1M
EPS
-$10.66
Total assets
$4.5M
Total debt
$0.00
Earnings yield
-546.67%

Price chart

0.951.582.212.843.47
PCSA 1D NASDAQ O1.86H1.95L1.83C1.93-0.01 (-0.52%)Vol18.50K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals Announces Key Leadership Appointments GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals Announces Corporate and Pipeline Progress Following Acquisition of Vidya Therapeutics GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals to Participate in Upcoming Investor Conferences GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Stock news Reviewing Stevanato Group (NYSE:STVN) and Heatwurx (NASDAQ:PCSA) Defense World
PCSAProcessa Pharmaceuticals, Inc. Stock news Heatwurx (NASDAQ:PCSA) versus Aquestive Therapeutics (NASDAQ:AQST) Critical Review Defense World
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Stock news PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study Zacks Investment Research
PCSAProcessa Pharmaceuticals, Inc. Stock news Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data? Benzinga
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer GlobeNewswire
PCSAProcessa Pharmaceuticals, Inc. Press release Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025 GlobeNewswire
See more
FAQ

Questions about Processa Pharmaceuticals, Inc.

What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog in Phase 2B clinical trials for pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase in Phase 1B clinical trials for me…
What is PCSA's market cap?
Processa Pharmaceuticals, Inc. (PCSA) is a listed stock with a live quote. The latest market cap on this page is $5.5M.
Where is Processa Pharmaceuticals, Inc. headquartered?
Processa Pharmaceuticals, Inc. is headquartered in Hanover, MD.
How do I get PCSA news from the API?
Call GET /v1/news?tickers=PCSA. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PCSA news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PCSA, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PCSA price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs